SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
Revenue from operations climbed 13% to Rs. 886.87 crore
Revenue from operations climbed 13% to Rs. 886.87 crore
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
Subscribe To Our Newsletter & Stay Updated